Takanobu Iwadare

Dr. Takanobu Iwadare

Shinshu University, Matsumoto, Japan
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2021 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
YYYuki Yamashita
Yuki Yamashita
SJSatoru Joshita
Satoru Joshita
ASAyumi Sugiura
Ayumi Sugiura
TYTomoo Yamazaki
Tomoo Yamazaki
HKHiroyuki Kobayashi
Hiroyuki Kobayashi
TUTakeji Umemura
Takeji Umemura

16 April 2024 in Communications Medicine
Verified
Journal Article
Open access
PDF file
TITakanobu Iwadare
Takanobu Iwadare
TKTakefumi Kimura
Takefumi Kimura
TOTaiki Okumura
Taiki Okumura
SWShun-Ichi Wakabayashi
Shun-Ichi Wakabayashi
TNTaro Nakajima
Taro Nakajima
TUTakeji Umemura
Takeji Umemura
Background: Circulating autotaxin (ATX) levels have been reported to correlate with liver inflammation activity and liver fibrosis severity in patients with non-alcoholic fatty liver disease (NAFLD). The objective of this study is to investigate whether serum ATX could predict liver-related events (LRE) in NAFLD patients. Methods: This retrospective investigation includes 309 biopsy-proven NAFLD patients registered at Shinshu University Hospital. All patients are followed for at least 1 year, during which time the prevalence of LRE, including newly developing hepatocellular carcinoma, hepatic encephalopathy, ascites, and esophagogastric varices, is investigated in relation to ATX levels at the time of liver biopsy. Results: During the median follow-up period of 7.0 years, LRE are observed in 20 patients (6.5%). The area under the receiver operating characteristic curve and cut-off value of serum ATX for predicting LRE are 0.81 and 1.227 mg/l, respectively. Multivariate Cox proportional hazards models for LRE determine ATX and advanced fibrosis as independently associated factors. Furthermore, in a competing risk analysis that considered non-liver-related death as a competing event, ATX (HR 2.29, 95% CI 1.22–4.30, p = 0.010) is identified as an independent factor associated with LRE, along with advanced fibrosis (HR 8.01, 95% CI 2.10–30.60, p = 0.002). The predictive utility of ATX for LRE is validated in an independent cohort. Conclusions: Serum ATX may serve as a predictive marker for LRE in patients with NAFLD.

7 November 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TITakanobu Iwadare
Takanobu Iwadare
TKTakefumi Kimura
Takefumi Kimura
NTNaoki Tanaka
Naoki Tanaka
TYTomoo Yamazaki
Tomoo Yamazaki
SWShun-Ichi Wakabayashi
Shun-Ichi Wakabayashi
TUTakeji Umemura
Takeji Umemura
Among several secreted glycoproteins belonging to the thrombospondin family, thrombospondin 2 (TSP2) is involved in various functions, including collagen/fibrin formation. Liver/serum TSP2 levels have been correlated to liver fibrosis stage and disease activity in nonalcoholic fatty liver disease. This study investigated whether serum TSP2 was associated with clinicopathological features in hepatitis C virus (HCV)-infected patients as well. A total of 350 patients with HCV who had undergone liver biopsy were retrospectively enrolled and divided into a discovery cohort (n = 270) and a validation cohort (n = 80). In the discovery cohort, serum TSP2 levels were moderately correlated with both liver fibrosis stage (r = 0.426, P < 0.0001) and activity grade (r = 0.435, P < 0.0001). The area under the receiver operating characteristic curve of TSP2 for predicting severe fibrosis (≥ F3) was 0.78 and comparable to or better than those of autotaxin (0.78), FIB-4 index (0.78), and APRI (0.76). The discovery cohort findings were closely replicated in the validation cohort. Moreover, comprehensive liver genetic analysis of HCV-infected patients confirmed that the expression of the THBS2 gene encoding TSP2 was significantly higher in severely fibrotic F4 than in F1 patients. Circulating TSP2 levels may reflect the severity of hepatic fibrosis/inflammation in HCV-infected patients.

4 November 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
TITakanobu Iwadare
Takanobu Iwadare
TKTakefumi Kimura
Takefumi Kimura
HKHideo Kunimoto
Hideo Kunimoto
Naoki TanakaNaoki Tanaka
Naoki Tanaka
SWShun-ichi Wakabayashi
Shun-ichi Wakabayashi
TUTakeji Umemura
Takeji Umemura
Aim: Pemafibrate (PEM) is a novel selective peroxisome proliferator-activated receptor alpha modulator that is effective for hypertriglyceridemia accompanying non-alcoholic fatty liver disease (HTG-NAFLD). This study aimed to identify the predictors of PEM efficacy for HTG-NAFLD in clinical practice. Methods: We retrospectively enrolled 88 HTG-NAFLD patients treated with PEM for 6 months for the analysis of routine blood and body composition testing. A PEM response was defined as a decrease in serum alanine aminotransferase (ALT) of >30% compared with pre-treatment level. The clinical features related to PEM responsiveness were statistically tested between responders and non-responders. Results: All 88 patients completed the 6 month drug regimen without any adverse effects. PEM treatment significantly decreased liver enzymes, triglycerides, and total cholesterol levels, without any detectable impact on body weight or body composition. Comparisons of baseline clinical features revealed female and greater aspartate aminotransferase (AST), ALT, and fat mass % levels to be significantly associated with a PEM response. The optimal cut-off values to predict responders as determined by receiver operating characteristic analysis were AST 45 U/L, ALT 60 U/L, and fat mass 37%. Conclusions: Female HTG-NAFLD patients with higher transaminase and fat mass % levels may be preferentially indicated for PEM treatment. Additional large-scale prospective studies are warranted to verify our results.

9 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
TOTaiki Okumura
Taiki Okumura
TKTakefumi Kimura
Takefumi Kimura
TITakanobu Iwadare
Takanobu Iwadare
SWShun-ichi Wakabayashi
Shun-ichi Wakabayashi
HKHiroyuki Kobayashi
Hiroyuki Kobayashi
TUTakeji Umemura
Takeji Umemura
Background: Serum C-reactive protein (CRP) is an established biomarker for acute inflammation and has been identified as a prognostic indicator for hepatocellular carcinoma (HCC). However, the significance of the serum CRP level, specifically in HCC patients treated with lenvatinib, remains unclear. Methods: We retrospectively analyzed 125 HCC patients who received lenvatinib treatment at six centers. Clinical characteristics were assessed to identify clinical associations between serum CRP and HCC prognosis. Results: The median overall serum CRP level was 0.29 mg/dL. The cohort was divided into two groups: the low-CRP group with a serum CRP < 0.5 mg/dL and the high-CRP group with a serum CRP ≥ 0.5 mg/dL. The low-CRP group exhibited significantly longer overall survival (OS) than the high-CRP group (22.9 vs. 7.8 months, p < 0.001). No significant difference was observed for progression-free survival (PFS) between the high- and low-CRP groups (9.8 vs. 8.4 months, p = 0.411), while time-to-treatment failure (TTF) was significantly longer in the low-CRP group (8.5 vs. 4.4 months, p = 0.007). The discontinuation rate due to poor performance status was significantly higher in the high-CRP group (p < 0.001). Conclusion: A baseline serum CRP level exceeding 0.5 mg/dL was identified as an unfavorable prognostic factor in HCC patients receiving lenvatinib treatment.

17 October 2024 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
TITakanobu Iwadare
Takanobu Iwadare
TKTakefumi Kimura
Takefumi Kimura
YYYuki Yamashita
Yuki Yamashita
TOTaiki Okumura
Taiki Okumura
SWShun-ichi Wakabayashi
Shun-ichi Wakabayashi
TUTakeji Umemura
Takeji Umemura
INTRODUCTION: A straightforward, reliable, and noninvasive method for predicting the development of liver-related events (LRE) in primary biliary cholangitis (PBC) has not been attained thus far. This study investigated whether serum autotaxin (ATX) could predict LRE in patients with PBC. METHODS: This retrospective multicenter investigation included 190 biopsy-proven untreated patients with PBC. All subjects were followed for at least 1 year, during which time the prevalence of LRE, including newly developing hepatocellular carcinoma, esophagogastric varices, ascites, and hepatic encephalopathy, was investigated in relation with ATX levels at the time of liver biopsy. RESULTS: During the median follow-up period of 9.7 years, LRE were observed in 22 patients (11.6%). The area under the receiver operating characteristic curve and cutoff value of serum ATX for predicting LRE were 0.80 and 1.086 mg/L, respectively. Patients with serum ATX ≥1.086 had a significantly higher cumulative incidence of LRE compared with patients with ATX < 1.086 (33.3% vs 3.6%, P < 0.00001). Notably, the predictive capability of ATX for LRE in patients with PBC surpassed that of FIB-4, ALBI, APRI, and Mac-2-binding protein glycan isomer. A multivariate Cox proportional hazards model revealed ATX as an independent associated factor for LRE (hazard ratio 6.24, 95% confidence interval 1.87–20.80, P = 0.003) along with Nakanuma stage (hazard ratio 2.75, 95% confidence interval 1.52–4.99, P < 0.001). These results were closely replicated in a serologically diagnosed PBC validation cohort (n = 32). DISCUSSION: Serum ATX levels may serve as a predictive marker for LRE in patients with PBC.